Health X reverses capital stance, now raising ₹154 cr debt after denying need
Management said no external capital needed for 5 years; now taking bank loans for warehouse. Also admitted JITHO transition hurt branded sales after denying any conflict with generic products.
What's new
- Q4FY26 revenue ₹356 cr (+22% YoY), gross margin 7.3% vs 5.9% a year ago.
- EBITDA loss cut 29% YoY to ₹20 cr; PAT near-breakeven at ₹1.4 cr loss for full year.
- JITHO generic medicines launched 15 SKUs, ₹30 lakh/month sales with 30-40% margin.
- Warehousing capex ₹424 cr, with ₹154 cr bank loans and ₹100 cr from treasury.
Themes from the call
Demand
B2B Retailer Shakti serves 62,000+ pharmacies, tracking ₹400 cr in Q1FY27, best ever. Northeast +50% YoY, North India +25-30%.
Margins
Gross margin expanded 100 bps to 7.5% for FY26. JITHO private label targets 30-40% margins, aiding blended EBITDA.
Capital allocation
₹424 cr capex for 8+ lakh sq ft warehouse network. Funding mix: ₹154 cr debt, ₹100 cr treasury, rest from operations. No equity dilution.
Guidance watch
- FY30 target: ₹6,000 cr revenue (₹4,000 cr B2B, ₹2,000 cr B2C), EBITDA margin 5%, PAT margin 4%, ROE 40%.
- FY27 EBITDA margin target of 1% reaffirmed.
Risk flags
- Reversal on capital needs raises questions about internal cash flow sufficiency and debt servicing.
- JITHO transition continues to disrupt branded sales; management expects normalization by year-end but timeline uncertain.
- Large capex execution risk: ₹424 cr spend on warehousing while still loss-making at EBITDA level.
Key quotes
-
"We remain confident in our long-term vision and continue to target 6,000 crores of revenue by FY30."
— Banwari Lal Mittal, prepared remarks -
"The total capex planned for this expansion is 234 crores. Out of that, we plan to take 154 crores in bank loans and deploy around 100 crores from the treasury."
— Health X management, Jun 2026 call
The brief
Health X delivered a strong operational quarter — revenue up 22%, gross margins expanding, and the B2B business hitting contribution-positive. The 'Shakti Surge' is real: Retailer Shakti is tracking a record ₹400 crore quarter in Q1FY27, and JITHO generics are gaining traction with a 30-40% margin profile. But two strategy reversals undercut the narrative. Six months ago, management said no external capital was needed for five years. Now it's taking ₹154 crore in bank loans for warehousing. The same call that once claimed zero conflict between generic and branded now admits the JITHO transition 'caused some disturbance' in branded sales. Management can't have it both ways. The FY30 ₹6,000 crore vision — with EBITDA margins of 5% — requires trust that the path is consistent. These reversals don't break the story, but they demand a closer look at how capital is being raised and how internally competing channels are managed.
Health X's operational turnaround is real, but the credibility gap on capital and channel conflict needs bridging.